Education
About Us
Working with TipRanks
Follow Us
Day One Biopharmaceuticals (DAWN)
NASDAQ:DAWN
DAWN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.64 - $16.76
Previous CloseN/A
Volume175.11K
Average Volume (3M)1.12M
Market Cap
$693.46M
Enterprise Value$219.85M
Total Cash (Recent Filing)$453.10M
Total Debt (Recent Filing)$3.00M
Price to Earnings (P/E)―
Beta1.54
Next Earnings
Nov 10, 2025EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding102,431,930
10 Day Avg. Volume1,203,849
30 Day Avg. Volume1,124,687
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.36
Price to Sales (P/S)9.04
P/FCF Ratio-14.78
Enterprise Value/Market Cap0.32
Enterprise Value/Revenue1.17
Enterprise Value/Gross Profit1.25
Enterprise Value/Ebitda-2.00
Forecast
1Y Price Target
$23.25Price Target Upside243.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Bulls Say, Bears Say
Bulls Say
Market ExpansionOjemda launch continues to expand on depth of patients per prescriber, with 60% of accounts now having multiple patients, and 20% with 5+, setting up for optimal growth.
Product PreferenceOjemda once weekly dosing in an outpatient setting is preferred over chemotherapy, which requires blood transfusions and causes bone toxicities.
Revenue GrowthOjemda's 2Q revenue rose by 10% and the company projects FY25 revenue to be between $140-$150MN, indicating continued growth.
Bears Say
Market Penetration ChallengesDAWN mostly traded in a tight range of $12-$15/share over the last 2 years but pulled back to $6-$8/share range as market penetration is now focusing beyond early adopters.
Prescribing PatternsThe investment debate is no longer about whether Ojemda can gain traction but rather about the durability of its slope, the timing of front-line expansion, and how pipeline diversification could extend Day One’s rare-disease style growth model.
Day One Biopharmaceuticals News
DAWN FAQ
What was Day One Biopharmaceuticals’s price range in the past 12 months?
Day One Biopharmaceuticals lowest stock price was $5.63 and its highest was $16.76 in the past 12 months.
What is Day One Biopharmaceuticals’s market cap?
Day One Biopharmaceuticals’s market cap is $693.46M.
When is Day One Biopharmaceuticals’s upcoming earnings report date?
Day One Biopharmaceuticals’s upcoming earnings report date is Nov 10, 2025 which is in 42 days.
How were Day One Biopharmaceuticals’s earnings last quarter?
Day One Biopharmaceuticals released its earnings results on Aug 05, 2025. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.357 by $0.067.
Is Day One Biopharmaceuticals overvalued?
According to Wall Street analysts Day One Biopharmaceuticals’s price is currently Undervalued.
Does Day One Biopharmaceuticals pay dividends?
Day One Biopharmaceuticals does not currently pay dividends.
What is Day One Biopharmaceuticals’s EPS estimate?
Day One Biopharmaceuticals’s EPS estimate is -0.29.
How many shares outstanding does Day One Biopharmaceuticals have?
Day One Biopharmaceuticals has 102,431,930 shares outstanding.
What happened to Day One Biopharmaceuticals’s price movement after its last earnings report?
Day One Biopharmaceuticals reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.357. Following the earnings report the stock price went down -15.698%.
Which hedge fund is a major shareholder of Day One Biopharmaceuticals?
Currently, no hedge funds are holding shares in DAWN
Day One Biopharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.25 (243.43% Upside)
$23.25 (243.43% Upside)
Blogger Sentiment
Bullish
DAWN Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 5.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 2.4%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.62%
12-Months-Change
Fundamentals
Return on Equity
-24.75%
Trailing 12-Months
Asset Growth
29.62%
Trailing 12-Months
Company Description
Day One Biopharmaceuticals
Day One Biopharmaceuticals (DAWN) is a clinical-stage biopharmaceutical company that focuses on developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. The company is dedicated to advancing innovative oncology treatments with an emphasis on improving the lives of children and adults living with cancer.
DAWN Company Deck
DAWN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong positive sentiment with significant achievements in revenue growth, prescription numbers, and financial stability. The momentum of OJEMDA's launch and the promising pipeline developments outweighed the single noted lowlight of discontinuing the VRK1 program.View all DAWN earnings summariesDAWN Stock 12 Month Forecast
Average Price Target
$23.25
▲(243.43% Upside)
Technical Analysis
Theravance Biopharma
―
Kura Oncology
―
Gossamer Bio
―
Maravai Lifesciences Holdings
―
Septerna, Inc.
―
Ownership Overview
4.19% Insiders
22.03% Mutual Funds
28.81% Other Institutional Investors
33.88% Public Companies and
Individual Investors